Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Splenic Hilar Nodes in Splenic Flexure Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04666883
Recruitment Status : Not yet recruiting
First Posted : December 14, 2020
Last Update Posted : December 29, 2020
Sponsor:
Information provided by (Responsible Party):
Giuseppe Sigismondo Sica, University of Rome Tor Vergata

Brief Summary:
Report the incidence of metastases to the splenic hilar lymphnodes from splenic flexure primaries. This mode of spread has not been previously characterized for these tumours.

Condition or disease Intervention/treatment
Colon Cancer Metastases, Lymphatic Other: Review of records and follow up

Layout table for study information
Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Aberrant Lympahtic Drainage of Splenic Flexure Cancer: Are Splenic Hilar Nodes Metastases an Underecognized Phenomenon?
Estimated Study Start Date : January 1, 2021
Estimated Primary Completion Date : March 1, 2021
Estimated Study Completion Date : March 1, 2021

Group/Cohort Intervention/treatment
Splenic flexure cancer patients
Splenic flexure cancer patients
Other: Review of records and follow up
Follow up to identify patients who developed splenic hilar nodal metastases




Primary Outcome Measures :
  1. Splenic hilum nodal metastases [ Time Frame: 5 years ]
    Splenic hilum nodal metastases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with cancer of the splenic flexure of the colon
Criteria

Inclusion Criteria:

  • All splenic flexure cancer patients

Exclusion Criteria:

  • No consent to data utilization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04666883


Contacts
Layout table for location contacts
Contact: Bruno Sensi, MD 3385352902 brunosensi@outlook.it
Contact: Giuseppe S Sica, MD, PhD 3385333659 sigisica@gmail.com

Locations
Layout table for location information
Italy
Policlinico Tor Vergata
Roma, RM, Italy, 00133
Contact: Bruno Sensi, MD    +39 3385352902    brunosensi@outlook.it   
Contact: Giuseppe S Sica, MD, PhD    +39 3385333659    sigisica@gmail.com   
Sponsors and Collaborators
University of Rome Tor Vergata
Layout table for additonal information
Responsible Party: Giuseppe Sigismondo Sica, Associate Professor, Head of Department, University of Rome Tor Vergata
ClinicalTrials.gov Identifier: NCT04666883    
Other Study ID Numbers: REGISTROSPERIMENTAZIONI/21
First Posted: December 14, 2020    Key Record Dates
Last Update Posted: December 29, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes